Aumolertinib with carboplatin–pemetrexed versus aumolertinib for nonsmall cell lung cancer with EGFR and concomitant tumor suppressor genes (ACROSS2): An open‐label, multicenter, randomized phase 3 study - Jian‐Chun Duan; Jia Zhong; Bo‐Yang Sun; Wen‐Hua Zhao; Lin Wu; Kai‐Lun Fei; Qian Chu; Qi‐Sen Guo; Qi‐Bin Song; Yan Yu; Da‐Xing Zhu; Xin‐Yan Liu; et al. (CA: A Cancer Journal for Clinicians, 2026)